Cabotegravir-rilpivirine regimen feasible in hospitals
09 Nov 2022
byTristan Manalac
A once-every-two-months (Q2M) dosing regimen of cabotegravir with rilpivirine long-acting (CAB+RPV LA) can be easily implemented in hospitals and draws high levels of acceptability, appropriateness, and feasibility feedback from healthcare staff, according to a study presented at the recently concluded 2022 HIV Glasgow Conference.